@inproceedings{inproceedings, title = {{A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS).}}, url = {{}}, year = {{2013}}, month = {{5}}, author = {{Talbot DC and Blackhall FH and Kowalski D and Ramlau R and Belper G and Grossi F and Lerchenmuller CA and Pinder MC and Mczger J and Danson S and Callies S et al}}, volume = {{31}}, journal = {{Journal of Clinical Oncology}}, note = {{Accessed on 2025/05/06}}}